AUTHORS
Tian Zeng, Xiudi Yang2, Rumeng Li3, Qingmei Han4, Bingbing Wen5, Jian Huang, MD, PhD6
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ABSTRACT
Introduction: Despite the availability of JAK inhibitors, many patients with MF have persistent splenomegaly, constitutional symptoms, or progressive anemia. Selinexor, an oral selective inhibitor of nuclear export, has demonstrated clinical activity in MF and may enhance the efficacy of JAK inhibition through complementary mechanisms. We report the preliminary efficacy and safety of selinexor plus gecacitinib in an ongoing prospective study (ChiCTR2600121951).
Methods: This ongoing prospective, single-center phase Ib/II study enrolled patients with intermediate- or high-risk myelofibrosis (primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF) who received selinexor plus gecacitinib. Selinexor was administered at 20 mg once or twice weekly in combination with gecacitinib (50 or 100 mg twice daily). Clinical efficacy was assessed by spleen response, symptom response, anemia response, and overall hematologic parameters during treatment. Spleen response was evaluated using spleen index measurements, symptom response was assessed by the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), and anemia response was defined according to the 2024 revised International Working Group–European LeukemiaNet (IWG-ELN) criteria. Safety was evaluated by treatment-emergent adverse events (TEAEs), which were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Data were summarized descriptively.
Results: A total of nine patients with myelofibrosis (MF) who received selinexor plus gecacitinib were included. The median age was 55 years, and most patients (88.9%) had previously received ruxolitinib. At baseline, patients had a substantial disease burden, with a median hemoglobin level of 85 g/L, a median lactate dehydrogenase (LDH) level of 794 U/L, and a median MPN-SAF Total Symptom Score (TSS) of 24. Constitutional symptoms were present in 55.6% of patients. Molecular profiling demonstrated a median of four somatic mutations per patient. The most frequently mutated genes were JAK2 V617F (55.6%) and ASXL1 (55.6%), indicating a cohort with high-risk molecular features and advanced disease burden. Four patients (44.4%) initiated selinexor at 20 mg twice weekly (BIW), whereas five (55.6%) received 20 mg once weekly (QW). Among evaluable patients, one patient in the BIW cohort achieved SVR35 at week 12. The mean spleen index reduction was −21.0% in the BIW cohort and −4.2% in the QW cohort. The mean change in MPN-SAF TSS was −7.1 points overall, including −9.3 points in the BIW cohort and −5.4 points in the QW cohort. Exploratory analyses showed greater symptom improvement in patients with ASXL1 mutations than in those without the mutation (mean TSS change, −10.8 vs. −2.5), whereas no significant difference was observed according to baseline severe anemia status. The most common treatment-emergent adverse event (TEAE) was nausea/vomiting (6/9, 66.7%), followed by anemia (4/9, 44.4%) and thrombocytopenia (4/9, 44.4%). Grade ≥3 TEAEs occurred in three patients (33.3%). Five patients (55.6%) required temporary treatment interruption because of TEAEs. Hematologic toxicities and fever were numerically more frequent in patients receiving selinexor 20 mg twice weekly than in those receiving once-weekly dosing, although no formal comparison was performed because of the limited sample size. No new safety signals were observed.
Conclusion: Selinexor plus gecacitinib demonstrated preliminary clinical activity with a manageable safety profile in heavily pretreated patients with myelofibrosis. These findings support further evaluation of this combination in larger prospective studies.
Acknowledgement: This research was supported by the National Natural Science Foundation of China (No. 82570191) and the Zhejiang Provincial Health High level Innovative Talent Project (2022-2026).
*Correspondence to: Jian Huang, M.D., Ph.D., Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China. E-mail: househuang@zju.edu.cn
DISCLOSURES
Jian Huang, MD, PhD: No relevant conflicts of interest to declare.